Showing 1 to 10 of 676 Clinical Trials
|
CLINICAL TRIAL Trial No ClinicalTrials.gov ID |
Principal Investigator
Coordinator |
||
|---|---|---|---|
|
A Phase 2 Study of Blinatumomab in Combination With Nivolumab, a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ? 1 to < 31 Years Old With First Relapse
COG-AALL1821 NCT04546399  Recruiting
|
CENTRE HOSPITALIER UNIVERSITAIRE SAINTE-JUSTINE
|
Acute Lymphocytic Leukemia |
Dr. Yvan Samson |
|
Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in
(Golden Gate Study) NCT04994717 Recruiting
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Acute Lymphocytic Leukemia |
Dr. Julie Bergeron Julie Trinh Lu 514-252-3400 poste 3336 Michel-Olivier Gratton 514-252-3400 poste 2397 |
|
A Phase 1/2 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
KO-MEN-001 NCT04067336 Recruiting
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Acute Myeloid Leukemia |
Dr. Julie Bergeron Julie Trinh Lu 514-252-3400 poste 3336 |
|
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
ENHANCE-3 NCT05079230 Recruiting
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Acute Myeloid Leukemia |
Dr. Julie Bergeron Julie Trinh Lu 514-252-3400 poste 3336 |
|
An Open-Label Phase 1a/1b Dose Escalation and Expansion Cohort Study of SL-172154 (SIRP?-Fc-CD40L) in Combination With Azacitidine or With Azacitidine and Venetoclax for the Treatment of Subjects With Higher-Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
SL03-OHD-104 NCT05275439 Recruiting
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
Acute Myeloid Leukemia Myelodysplastic Syndrome |
Dr. Sarit Assouline Maria Kluchnyk 514-340-8222 poste 26394 |
|
A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients With Acute Myeloid Leukemia Who Are at High-Risk for Leukemia Relapse Following Hematopoietic Cell Transplantation
VBP101 NCT04849910 Recruiting
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Acute Myeloid Leukemia |
Dr. Nadia Bambace Olivier Cormier 514-252-3400 poste 5966 |
|
A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine After Allogeneic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia
VIALE-T NCT04161885 Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Acute Myeloid Leukemia |
Dr. Gizelle Propadi Judit Kokai 438-888-1582 |
|
Capturing Canadian Real-World Data for AML Chemotherapy Ineligible Patients on Venetoclax
LIVEN (P23-363) NCT05424562 Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Acute Myeloid Leukemia |
Dr. John Storring Judit Kokai 438-888-1582 |
|
A Phase 1 Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
LOXO-IDH-20001 NCT04603001 Recruiting
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
Acute Myeloid Leukemia Myelodysplastic Syndrome |
Dr. Sarit Assouline |
|
Banque des cellules leucémique du Québec
banque cellules leucémique Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
Acute Myeloid Leukemia |
Dr. Robert Delage Linda Vallée 418-649-0252 poste 66602 |
Groupe d'étude en oncologie du Québec